SND-562

**SND-562** is a preclinical, first-in-class small-molecule anticancer candidate being developed by Floratek Pharma and described publicly as a **CKAP4 inhibitor**. Publicly available sponsor and pipeline-tracking sources indicate that the program is being explored primarily for **ovarian cancer**, **pancreatic cancer**, and in some sources **endometrial carcinoma**, with discovery work emerging from efforts around polyphenolic CKAP4-directed compounds. CKAP4 is implicated as a cell-surface receptor involved in pro-tumor signaling, including interaction with DKK1, so SND-562 appears intended to suppress CKAP4-driven tumor growth signaling rather than act as a cytotoxic chemotherapy in the classic sense. The asset appears to remain **preclinical**, and detailed structural, pharmacokinetic, formulation, and clinical-trial information has not been clearly disclosed in the public domain.